Meanwhile, a growing number of studies have combined genomics, radiology, proteomics data, and pathology to estimate PD-L1 expression levels, TMB, and tumor microenvironment (TME) or predict the response to immunotherapy and side effects in patients with cancer [18–20]. The gene discussed is CD274; the disease is neoplasm.